The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Open accessAbstract
BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary end point was the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm). RESULTS: At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy (adjusted difference, -0.4 percentage points; 95% confidence interval [CI], -2.8 to 2.1), a result that met the criterion for noninferiority for the primary end point (margin, 6 percentage points). An HIV-1 RNA level of less than 50 copies per milliliter at week 48 was found in 93.6% who received long-acting therapy and in 93.3% who received oral therapy (adjusted difference, 0.4 percentage points; 95% CI, -3.7 to 4.5), a result that met the criterion for noninferiority for this end point (margin, -10 percentage points). Of the participants who received long-acting therapy, 86% reported injection-site reactions (median duration, 3 days; mild or moderate severity, 99% of cases); 4 participants withdrew from the trial for injection-related reasons. Grade 3 or higher adverse events and events that met liver-related stopping criteria occurred in 11% and 2%, respectively, who received long-acting therapy and in 4% and 1% who received oral therapy. Treatment satisfaction increased after participants switched to long-acting therapy; 91% preferred long-acting therapy at week 48. CONCLUSIONS: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir-abacavir-lamivudine with regard to maintaining HIV-1 suppression. Injection-site reactions were common. (Funded by ViiV Healthcare and Janssen; FLAIR ClinicalTrials.gov number, NCT02938520.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Blanc, F.-X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Madec, Y., Marcy, O., Chan, S., Prak, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013911 · Cited by 612
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V., Bredeek, F., Smith, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1904398 · Cited by 594
Self-citationThe Survival Benefits of AIDS Treatment in the United States
Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., Weinstein, M. C., & Freedberg, K. A. (2006) · The Journal of Infectious Diseases · doi:10.1086/505147 · Cited by 581
Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 499
Self-citationHemelaar, J., Elangovan, R., Yun, J., Dickson-Tetteh, L., Fleminger, I., Kirtley, S., Williams, B., Gouws-Williams, E., Ghys, P. D., Abimiku, A. G., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30647-9 · Cited by 405
Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., Hung, C.-C., Rockstroh, J. K., Girard, P.-M., Sievers, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32462-0 · Cited by 387
Self-citationLlibre, J. M., Hung, C.-C., Brinson, C., Castelli, F., Girard, P.-M., Kahl, L. P., Blair, E. A., Angelis, K., Wynne, B., Vandermeulen, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33095-7 · Cited by 358
Self-citationAdherence to Highly Active Antiretroviral Therapy (HAART): A Meta-Analysis
Ortego, C., Huedo-Medina, T. B., Llorca, J., Sevilla, L., Santos, P., Rodríguez, E., Warren, M. R., & Vejo, J. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-9942-x · Cited by 310
Drug safety assessment in clinical trials: methodological challenges and opportunities
Singh, S., & Loke, Y. K. (2012) · Trials · doi:10.1186/1745-6215-13-138 · Cited by 227
Margolis, D. A., Brinson, C. C., Smith, G. H. R., de Vente, J., Hagins, D. P., Eron, J. J., Griffith, S. K., Clair, M. H. S., Stevens, M. C., Williams, P. E., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00152-8 · Cited by 204
Self-citationWilliams, J. K., Sayles, H. R., Meza, J. L., Sayre, P., Sandkovsky, U., Gendelman, H. E., Flexner, C. W., & Swindells, S. (2013) · Nanomedicine · doi:10.2217/nnm.12.214 · Cited by 104
Validation of the HIV Treatment Satisfaction Questionnaire (HIVTSQ)
Woodcock, A. J., & Bradley, C. (2001) · Quality of Life Research · doi:10.1023/a:1013050904635 · Cited by 87
Asking about adherence – from flipping the coin to strong evidence
Glass, T. R., & Cavassini, M. L. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14016 · Cited by 28
Crauwels, H. M., van Schaick, E., Heeswijk, R. G. V., Vanveggel, S., Boven, K., & Vis, P. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-s4-p186 · Cited by 24
Self-citation
Cited by
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., Cabello, R., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 900
Self-citationLong-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V., Bredeek, F., Smith, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1904398 · Cited by 594
Self-citationOvercoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Saag, M. S., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Thompson, M. A., Sax, P. E., Smith, D. M., Benson, C. A., Buchbinder, S. P., del Rio, C., et al. (2020) · JAMA · doi:10.1001/jama.2020.17025 · Cited by 471
Overton, E. T., Richmond, G., Rizzardini, G., Jaeger, H., Orrell, C., Nagimova, F., Bredeek, F., García Deltoro, M., Swindells, S., Andrade-Villanueva, J. F., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32666-0 · Cited by 377
Self-citation
Metadata
- Authors
- Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P.-M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., Philibert, P., Lombaard, J., St. Clair, M., Crauwels, H., Ford, S. L., Patel, P., Chounta, V., D’Amico, R., Vanveggel, S., Dorey, D., Cutrell, A., Griffith, S., Margolis, D. A., Williams, P. E., Parys, W., Smith, K. Y., & Spreen, W. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-19
- Volume
- 382
- Issue
- 12
- Pages
- 1124-1135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3010513804
- Cited by
- 487
- References
- 16
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.